Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial
Eva Ciruelos(Hospital Universitario 12 De Octubre), Aleix Prat(Hospital Clínic de Barcelona), Blanca Cantos(Hospital Universitario Puerta de Hierro Majadahonda), Sònia Pernas, Guillermo Villacampa(Vall d'Hebron Institut de Recerca), J.M. Ferrero-Cafiero(Solti), Juan de la Haba-Rodríguez(Instituto Maimónides de Investigación Biomédica de Córdoba), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Antonio Mulero‐Sánchez(Oncode Institute), Javier Cortés(Villa Maria Hospital), Lorea Villanueva, Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Patricia Galván(Vall d'Hebron Institute of Oncology), Mireia Mele(University of Padua), José Ponce(GEICAM – Spanish Breast Cancer Group), Esther Sanfeliu(Hospital Clínic de Barcelona), Eduardo Martínez de Dueñas(Consorcio Hospitalario Provincial de Castellón), Santiago Escrivá-de-Romaní(Unknown), Patricia Villagrasa, Álvaro Montaño(Hospital Universitario Virgen del Rocío), Antonia Perelló, Ana López-González(GEICAM – Spanish Breast Cancer Group), Xavier González(Breast Cancer Research Foundation)
Cited by 0
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k